[Targeting epidermal growth factor receptor in cancer of the breast]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The erbB receptor family, part of the receptor tyrosine kinase superfamily, is crucial in normal breast development and breast cancer progression.
• Overexpression of erbB receptors is linked to poor prognosis, increased tumor invasiveness, and resistance to standard therapies like chemotherapy and hormonotherapy.

Purpose of the Study:

• To explore the potential of targeting the epidermal growth factor receptor (EGFR) in breast cancer treatment.
• To evaluate the efficacy of EGFR-targeting agents, particularly tyrosine kinase inhibitors, in various breast cancer contexts.

Main Methods:

• Review of experimental data on EGFR targeting strategies, including tyrosine kinase inhibitors and monoclonal antibodies.
• Analysis of studies investigating the combination of EGFR inhibitors with hormonotherapy, chemotherapy, and trastuzumab.
• Examination of in situ carcinoma studies regarding chemoprevention roles.

Main Results:

• Tyrosine kinase inhibitors show activity as monotherapy and in combination with other breast cancer treatments.
• EGFR inhibitors, such as Iressa, may prevent or overcome hormone resistance when combined with hormonotherapy.
• Evidence suggests tyrosine kinase inhibitors could play a role in breast cancer chemoprevention.

Conclusions:

• Targeting EGFR is a viable strategy for a broad range of breast tumors, from early to advanced stages, and across hormone receptor statuses.
• The complexity of the erbB network necessitates targeting multiple molecular sites and characterizing tumor profiles for effective patient selection.